SCHEMBL20705144

SCHEMBL20705144

CNC(=O)C(CCCN)NC(=O)O

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 2/20 0.45
MMP3 P08254 2/20 0.45
MMP9 P14780 1/20 0.45
SIRT6 Q8N6T7 1/20 0.41
SIRT1 Q96EB6 1/20 0.41
FOLH1 Q04609 1/20 0.40
BMP1 P13497 3/20 0.40
EHMT2 Q96KQ7 2/20 0.38
DPP4 P27487 1/20 0.36
DPP8 Q6V1X1 1/20 0.36
DPP9 Q86TI2 1/20 0.36
DPP7 Q9UHL4 1/20 0.36
CPB2 Q96IY4 1/20 0.36
NMT2 O60551 1/20 0.35
NMT1 P30419 1/20 0.35
SLC6A5 Q9Y345 1/20 0.35
GSR P00390 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20705272 0.95 SIRT6 (0.47) MMP1MMP3MMP9SIRT6SIRT1
SCHEMBL13698293 0.85 SIRT6 (0.55) MMP1MMP3MMP9SIRT6SIRT1
SCHEMBL25556371 0.82 MMP1 (0.40) MMP1MMP3MMP9SIRT6SIRT1
SCHEMBL13331678 0.80 SIRT6 (0.61) MMP1MMP3MMP9SIRT6SIRT1
SCHEMBL2789981 0.80 SIRT6 (0.61) MMP1MMP3MMP9SIRT6SIRT1
SCHEMBL19115851 0.79 SIRT1 (0.42) MMP1MMP3SIRT6SIRT1FOLH1
SCHEMBL23610945 0.79 SIRT1 (0.60) SIRT6SIRT1FOLH1DPP7CPB2
SCHEMBL7284768 0.79 SIRT6 (0.46) MMP1MMP3MMP9SIRT6SIRT1
SCHEMBL20705261 0.78 SIRT1 (0.43) MMP1MMP3SIRT6SIRT1FOLH1
SCHEMBL12560087 0.78 GRIN1 (0.53) MMP1MMP3MMP9EHMT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199602-A1 INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-06-20 US disclosed
US-11905285-B2 Inhibitors of plasma kallikrein and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-02-20 US disclosed
US-20220056028-A1 INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-02-24 US disclosed
US-11168083-B2 Inhibitors of Plasma Kallikrein and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-11-09 US disclosed
US-20200239463-A1 INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF DYAX CORP. (US) 2020-07-30 US disclosed
EP-3661922-A1 INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF Dyax Corp. (US) 2020-06-10 EP disclosed
WO-2019028362-A1 INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF DYAX CORP. (US) 2019-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199602-A1 INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF KLKB1, KLK1, KLK5 MMP1 264/4885MMP3 350/4885MMP9 231/4885
US-11168083-B2 Inhibitors of Plasma Kallikrein and uses thereof KLKB1, KLK1, KLK5 MMP1 264/4885MMP3 350/4885MMP9 231/4885
US-20200239463-A1 INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF KLKB1, KLK1, KLK5 MMP1 264/4885MMP3 350/4885MMP9 231/4885
US-20220056028-A1 INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF KLKB1, KLK1, KLK5 MMP1 264/4885MMP3 350/4885MMP9 231/4885
US-11905285-B2 Inhibitors of plasma kallikrein and uses thereof KLKB1, KLK1, KLK5 MMP1 264/4885MMP3 350/4885MMP9 231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.